Abstract:The increasing knowledge of molecular drivers of tumorigenesis has fueled targeted cancer therapies based on specific inhibitors. Beyond “classic” oncogene inhibitors, epigenetic therapy is an emerging field. Epigenetic alterations can occur at any time during cancer progression, altering the structure of the chromatin, the accessibility for transcription factors and thus the transcription of genes. They rely on post-translational histone modifications, particularly the acetylation of histone lysine residues, and are determined by the inverse action of histone acetyltransferases (HATs) and histone deacetylases (HDACs). Importantly, HDACs are often aberrantly overexpressed, predominantly leading to the transcriptional repression of tumor suppressor genes. Thus, histone deacetylase inhibitors (HDACis) are powerful drugs, with some already approved for certain hematological cancers. Albeit HDACis show activity in solid tumors as well, further refinement and the development of novel drugs are needed. This review describes the capability of HDACis to influence various pathways and, based on this knowledge, gives a comprehensive overview of various preclinical and clinical studies on solid tumors. A particular focus is placed on strategies for achieving higher efficacy by combination therapies, including phosphoinositide 3-kinase (PI3K)-EGFR inhibitors and hormone- or immunotherapy. This also includes new bifunctional inhibitors as well as novel approaches for HDAC degradation via PROteolysis-TArgeting Chimeras (PROTACs).

Histone Deacetylase Inhibitors Merged with Protein Tyrosine Kinase Inhibitors.

Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

Selective Histone Deacetylase Inhibitors with Anticancer Activity.

Cyclic Peptide Histone Deacetylase Inhibitors

HDAC-targeting epigenetic modulators for cancer immunotherapy

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective

Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

Recent Advances in Multi-target Drugs Targeting Protein Kinases and Histone Deacetylases in Cancer Therapy

Technologies of Targeting Histone Deacetylase in Drug Discovery: Current Progress and Emerging Prospects.

Histone Deacetylase (HDAC) Inhibitors in Cancer: a Patent Review (2017-Present)

Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy

Targeting histone deacetylases for cancer therapy: Trends and challenges

Advances in targeting histone deacetylase for treatment of solid tumors

Histone Deacetylase Inhibitors as Anticancer Drugs

Hydroxamic Acid Hybrids: Histone Deacetylase Inhibitors with Anticancer Therapeutic Potency

Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.

Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator